Printer Friendly

SYNCOR ANNOUNCES RECORD FIRST QUARTER RESULTS

 SYNCOR ANNOUNCES RECORD FIRST QUARTER RESULTS
 CHATSWORTH, Calif., Sept. 17 /PRNewswire/ -- Syncor International


Corporation (NASDAQ: SCOR) today announced record sales and earnings for the first quarter ended Aug. 31, 1992. This is also the 13th consecutive quarter-to-quarter increase in sales and earnings.
 Sales in the first quarter of fiscal 1993 increased 25.9 percent to a record $59.6 million, up from $47.3 million in the first quarter of fiscal 1992. Net income increased 39.4 percent to $2.2 million in the first quarter of fiscal 1993 compared to $1.6 million in the first quarter of fiscal 1992. Earnings per share increased 39.7 percent to $.21 per share in fiscal 1993, up from the $.15 per share in fiscal 1992.
 "We attribute recent outstanding quarter-to-quarter growth in sales and earnings to the continued success of two new cardiology products, DuPont Merck's 'I.V. Persantine(R)' (manufactured and distributed by DuPont Merck under license from Boehringer Ingleheim Pharmaceuticals) and 'Cardiolite(R).' Nuclear medicine will continue the recent accelerated growth and change as additional imaging agents receive regulatory approval," said Gene R. McGrevin, Syncor's president and chief executive officer."
 "We are conscious of the need to continue investing in our core business to increase our share of the industry's growth. We expect to continue expanding our national pharmacy network through new start-ups; or the acquisition of existing independent pharmacies, as well as through the exploration of related new business concepts. Management is committed to investing the human and financial resources necessary to further enhance Syncor's leadership position in technologically advanced pharmacy services," added Mr. McGrevin.
 Syncor International operates an expanding nationwide network of 95 nuclear pharmacy service centers and 14 home care pharmacies. The company prepares and delivers patient specific intravenous drugs and solutions for use in diagnostic imaging and a complete range of products for infusion therapy. Syncor services over 6,000 hospitals, clinics, physicians' offices, nursing facilities, and home-based patients. Syncor is the only national pharmacy network of its kind that provides this combination of diagnostic, therapeutic, and monitoring services to hospitals and alternate site markets.
 SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
 Consolidated Statements of Operations
 (In thousands, except per share data, unaudited)
 Three months ended Aug. 31 1992 1991
 Net sales $59,595 $47,332
 Cost of sales 39,200 30,453
 Gross profit 20,395 16,879
 Operating, selling and administrative
 expenses 16,714 14,178
 Operating income 3,681 2,701
 Other income (expense), net 22 31
 Pre tax income 3,703 2,732
 Provision for income taxes 1,463 1,121
 Net income 2,240 1,611
 Net income per share of common
 stock and common stock equivalents 0.21 0.15
 Weighted average common stock
 and common stock equivalents 10,632 10,685
 Net income per share of common
 stock and common stock equivalents
 assuming full dilution 0.21 0.15
 Weighted average common stock and
 common stock equivalents assuming
 full dilution 10,748 10,737
 -0- 9/17/92
 /CONTACT: Michael E. Mikity, vice president-finance of Syncor International Corporation, 818-717-4610, or Susan Noonan of Noonan/Russo Communications, Inc., 212-979-9180, for Syncor International Corporation/
 (SCOR) CO: Syncor International Corporation ST: California IN: MTC SU: ERN


SM-OS -- NY011 -- 0479 09/17/92 09:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1992
Words:542
Previous Article:FRANKLIN QUEST ANNOUNCES NEW POCKET DAY PLANNER AND TIME MANAGEMENT SOFTWARE FOR MACINTOSH
Next Article:DECATUR FEDERAL SIGNS DEPARTMENT OF JUSTICE CONSENT DECREE
Topics:


Related Articles
SYNCOR ANNOUNCES RECORD SECOND QUARTER, SIX MONTH RESULTS
SYNCOR OPENS POSITRON EMISSION TOMOGRAPHY CENTER AND EXPANDS NATIONAL PHARMACY NETWORK
SYNCOR ANNOUNCES RECORD THIRD QUARTER AND NINE MONTH RESULTS
SYNCOR ANNOUNCES RECORD FOURTH QUARTER AND YEAR END RESULTS
SYNCOR ANNOUNCES RECORD SECOND QUARTER AND SIX MONTH RESULTS
Immunomedics Forges Agreement with Syncor for U.S. Distribution of Cancer Imaging Agent Through its 118 Radiopharmacies
IMAGING FIRM GOING TO SYNCOR.
CARDINAL HEALTH NET UP 28% IN 3RD QUARTER.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters